Glioblastoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• MGMT 20
• EGFR 14
• IDH 10
• STAT3 3
• TP53 0
• AKT 0
• mTOR 1
• PI3K 1
• PD-1 7
• ERK 0
• PD-L1 5
• STING 0
• YAP 0
• B7-H3 7
• MAPK 0
• PARP 1
• CTNNB1 0
• PTEN 1
• VEGF 5
• AMPK 0
• BRAF 1
• TERT 3
• FGFR 1
• PRMT5 5
• CDK4/6 0
• HDAC 0
• HIF-1 1
• IL-6 0
• NRF2 0
• PSMA 4
• MYC 2
• COX-2 0
• CXCR4 0
• EZH2 0
• CD47 0
• HER2 2
• JAK 0
• MEK 0
• MET 1
• METTL3 0
• TLR4 0
• ATM 2
• GPX4 0
• MDM2 0
• BCL-2 0
• CDKN2A 0
• CTLA-4 0
• FAK 0
• HSP90 0
• JNK 0
• MMP-9 1
• TNF 0
• CD19 0
• NF1 1
• NTRK 1
• TREM2 0
• AR 0
• CD40 1
• HMGB1 0
• IDO1 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R21

  Tackling tumor recurrence in pediatric brain tumors: identification of epigenetic memory and tumor microenvironment conducive to tumor recurrence in an inducible and reversible H3K27M murine model.

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$401,115 awarded in fiscal year 2026· until Aug 2028

• NIH NINDS · R03

  Uncovering glycoRNA landscape in glioblastoma as a novel layer of immune evasion

  University of Texas Hlth Sci Ctr Houston· Houston, United States· US$78,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R42

  Targeting EGFR-Mutant NSCLC CNS Metastases with CM93, a Novel Brain-Penetrant EGFR Inhibitor

  Crimson Biopharm Inc· Brookline, United States· US$1,125,000 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · F31

  Co-engineering CAR T cells and CAR macrophages with synthetic cytokine signaling for glioblastoma immunotherapy

  Stanford University· Stanford, United States· US$50,114 awarded in fiscal year 2026· until Sept 2029

• NIH NINDS · R21

  Regulation of Glioma Cell State Transition and Therapy Response by RNA Alternative Splicing

  Medical University of South Carolina· Charleston, United States· US$188,750 awarded in fiscal year 2026· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of tRNA-dependent translational control in the onset and progression of Glioblastoma. (tRansGlio)

  Institut National de la Sante Et de la Recherche Medicale· Paris, France· EU contribution €226,421· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the mechanisms driving cancer cell DORMancy and REcurrence in glioblastoma (DORMIRE)

  Universite de Lausanne· Lausanne, Switzerland· EU contribution €292,119· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  ECLIPSE: Unveiling Brain Tumor Metabolism with Advanced In Vivo MRI

  Universitair Medisch Centrum Utrecht· Utrecht, Netherlands· EU contribution €2,099,257· until May 2032

• European Commission (Horizon Europe) · HORIZON-ERC

  Spatiotemporal Mapping of Immune Cell Behavior in Glioblastoma (VideoTranscriptomics)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €1,484,173· until Jan 2032

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Training Europe’s Future Leaders in AI-driven Neuro-Oncology Diagnostics and Discovery (FutureMIND)

  Ruprecht-Karls-Universitaet Heidelberg· Heidelberg, Germany· EU contribution €4,379,817· until Dec 2030· 8 countries

  The disease is named only in the funder's project summary, not in the title.

10 of 821 running projects, newest first. Listed amounts together: US$403.5m + €179.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 93
• Organoids 33
• Mendelian Randomization Analysis 14
• CRISPR-Cas Systems 11
• Gene Expression Profiling 151
• Sequence Analysis, RNA 10
• Exome Sequencing 2
• Proteomics 47
• Metabolomics 21
• Mass Spectrometry 9
• Flow Cytometry 16
• Immunohistochemistry 22
• Liquid Biopsy 10
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 226
• Positron-Emission Tomography 38
• Magnetic Resonance Imaging 234
• Machine Learning 266
• Deep Learning 43
• Cohort Studies 54
• Genome-Wide Association Study 13

• Comprehensive immune profiling of human peripheral blood mononuclear cells using two complementary spectral flow cytometry panels encompassing 60 unique markers.

  Front Immunol, Sept 2026

• [Research of interaction of fluorescent anti-CD133 DNA aptamers with glioblastoma cell cultures using flow cytometry].

  Zh Vopr Neirokhir Im N N Burdenko, Jan 2026

• Isolation and Flow Cytometric Analysis of Natural Killer Cells from Human Glioblastoma Multiforme (GBM) Tissues.

  Curr Protoc, Nov 2025

• Nanomedicine based curcumin and doxorubicin combination treatment of glioblastoma with scFv-targeted micelles: In vitro evaluation on 2D and 3D tumor models.

  Eur J Pharm Biopharm, Aug 2016

• Involvement of autophagy in melatonin-induced cytotoxicity in glioma-initiating cells.

  J Pineal Res, Sept 2014

• Gracilaria lemaneiformis polysaccharide as integrin-targeting surface decorator of selenium nanoparticles to achieve enhanced anticancer efficacy.

  ACS Appl Mater Interfaces, Aug 2014

• Recombinant receptor-binding domain of diphtheria toxin increases the potency of curcumin by enhancing cellular uptake.

  Mol Pharm, Nov 2013

• Distinct sulfonation activities in resveratrol-sensitive and resveratrol-insensitive human glioblastoma cells.

  FEBS J, May 2012

• Antiglioma activity of curcumin-loaded lipid nanoparticles and its enhanced bioavailability in brain tissue for effective glioblastoma therapy.

  Acta Biomater, Apr 2012

• Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiforme primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest.

  Free Radic Biol Med, Feb 2012

See which targets of this disease your abstract mentions, and go to the people working on them.